Racial and Ethnic Disparities in Preoperative Surgical Wait Time and Renal Cell Carcinoma Tumor Characteristics
- PMID: 34574957
- PMCID: PMC8471651
- DOI: 10.3390/healthcare9091183
Racial and Ethnic Disparities in Preoperative Surgical Wait Time and Renal Cell Carcinoma Tumor Characteristics
Abstract
Racial/ethnic minority groups have a disproportionate burden of kidney cancer. The objective of this study was to assess if race/ethnicity was associated with a longer surgical wait time (SWT) and upstaging in the pre-COVID-19 pandemic time with a special focus on Hispanic Americans (HAs) and American Indian/Alaska Natives (AIs/ANs). Medical records of renal cell carcinoma (RCC) patients who underwent nephrectomy between 2010 and 2020 were retrospectively reviewed (n = 489). Patients with a prior cancer diagnosis were excluded. SWT was defined as the date of diagnostic imaging examination to date of nephrectomy. Out of a total of 363 patients included, 34.2% were HAs and 8.3% were AIs/ANs. While 49.2% of HA patients experienced a longer SWT (≥90 days), 36.1% of Non-Hispanic White (NHW) patients experienced a longer SWT. Longer SWT had no statistically significant impact on tumor characteristics. Patients with public insurance coverage had increased odds of longer SWT (OR 2.89, 95% CI: 1.53-5.45). Public insurance coverage represented 66.1% HA and 70.0% AIs/ANs compared to 56.7% in NHWs. Compared to NHWs, HAs had higher odds for longer SWT in patients with early-stage RCC (OR, 2.38; 95% CI: 1.25-4.53). HAs (OR 2.24, 95% CI: 1.07-4.66) and AIs/ANs (OR 3.79, 95% CI: 1.32-10.88) had greater odds of upstaging compared to NHWs. While a delay in surgical care for early-stage RCC is safe in a general population, it may negatively impact high-risk populations, such as HAs who have a prolonged SWT or choose active surveillance.
Keywords: American Indians; Latinos; cancer health disparities; surgical disparities.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Katims A.B., Razdan S., Eilender B.M., Wiklund P., Tewari A.K., Kyprianou N., Badani K.K., Mehrazin R. Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable. Urol. Oncol. 2020;38:783–792. doi: 10.1016/j.urolonc.2020.06.028. - DOI - PMC - PubMed
-
- Srivastava A., Patel H.V., Kim S., Shinder B., Sterling J., Tabakin A.L., Polotti C.F., Saraiya B., Mayer T., Kim I.Y., et al. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urol. Oncol. 2020;39:247–257. doi: 10.1016/j.urolonc.2020.10.012. - DOI - PMC - PubMed
-
- Valencia C.I., Asmar S., Hsu C.H., Gachupin F.C., Wong A.C., Chipollini J., Lee B.R., Batai K. Renal cell carcinoma health disparities in stage and mortality among American Indians/Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry data. Cancers. 2021;13:990. doi: 10.3390/cancers13050990. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources